Stefaniuk P, Cianciara J,Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol,2010,16:418-424.
[2]
Li YH,Lei T,Chen XD,et al. Molecular cloning,chromosomal location and expression pattern of porcine CIDEa and CIDEc[J]. Mol Biol Rep,2009,36:575-582.
[3]
Aravalli RN,Steer CJ,Cressman EN.Molecular 16 mechanisms of hepatocellular carcinoma[J].Hepatology,2008,48:2047-2063.
[4]
Margueron R, Reinberg D.The Polycomb complex PRC2 and its mark in life[J]. Nature, 2011, 469(7330):343-397.
Yu J,Cao Q,Mehra R,et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer[J].Cancer Cell,2007,12:419-431.
[7]
Yoon KA,Gil HJ,Han J. Genetic poly mofphisms in the polycomb group gene EZH2 and the risk of lung ancer[J]. J Thorac Oncol, 2010, 5(1):10-16.
[8]
Deb G, Thakur VS, Gupta S. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond[J]. Epigenetics,2013, 8(5):464-476.
[9]
Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer[J]. Protein Cell, 2013, 4(5):331-341.
[10]
Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer[J]. Clin Cancer Res, 2006, 12:1168-1174.
[11]
Fluge O, Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis[J]. Br J Cancer, 2009, 101:1282-1289.
[12]
Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast[J]. J Clin Oncol, 2006, 24:268-273.
[13]
Yu J,Rhodes DR, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome[J]. Cancer Res,2007,67:10657-10663.
[14]
Komindr A, Praditphol N, Suphanpayak S, et al. Correlation of HBV and HCV with CH,LC,HCC in liver biopsied tissue at Rajavithi Hospital[J]. J Med Assoc Thai, 2005, 88(6):788-809.
[15]
Matsumura M,Shiratori Y,Niwa Y,et al. Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma[J].J Hepatol, 1999, 31(2):332-339.
[16]
Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who undervent hepatectomy for small hepatocellular carcinoma[J].Cancer,2001,91(8):1479-1486.
[17]
Karanikolas BD, Figueiredo ML, Wu L. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line[J]. Mol Cancer Res, 2009, 7:1456-1465.
